Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $52M | $-250M | $-266M | $-217M | -40.6% | -18.5% | 37.4% |
| 2024 | $64M | $-176M | $-194M | $-136M | -61.4% | 9.0% | 139.7% |
| 2023 | $58M | $-66M | $-81M | $-76M | -88.6% | 13.5% | 13.7% |
| 2022 | $51M | $-62M | $-71M | $-63M | -200.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 51.95 |
| Operating Revenue | 51.95 |
| Cost Of Revenue | 6.57 |
| Gross Profit | 45.38 |
| Operating Expense | 315.39 |
| Research And Development | 197.10 |
| Selling General And Administration | 118.30 |
| Total Expenses | 321.97 |
| Operating Income | -270.02 |
| Total Operating Income As Reported | -270.02 |
| EBITDA | -249.78 |
| Normalized EBITDA | -247.31 |
| EBIT | -254.10 |
| Interest Income | 18.36 |
| Interest Expense | 11.84 |
| Net Interest Income | 6.52 |
| Other Non Operating Income Expenses | 0.03 |
| Other Income Expense | -2.44 |
| Interest Income Non Operating | 18.36 |
| Interest Expense Non Operating | 11.84 |
| Net Non Operating Interest Income Expense | 6.52 |
| Pretax Income | -265.94 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -265.94 |
| Net Income From Continuing And Discontinued Operation | -265.94 |
| Net Income From Continuing Operation Net Minority Interest | -265.94 |
| Net Income | -265.94 |
| Net Income Common Stockholders | -265.94 |
| Net Income Including Noncontrolling Interests | -265.94 |
| Normalized Income | -263.47 |
| Diluted NI Availto Com Stockholders | -265.94 |
| Basic Average Shares | 187.24 |
| Diluted Average Shares | 187.24 |
| Reconciled Depreciation | 4.32 |
| Reconciled Cost Of Revenue | 6.57 |
| Total Unusual Items | -2.47 |
| Total Unusual Items Excluding Goodwill | -2.47 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Gain On Sale Of Security | -2.47 |
| General And Administrative Expense | 112.15 |
| Other Gand A | 35.41 |
| Salaries And Wages | 76.74 |
| Selling And Marketing Expense | 6.15 |
| Average Dilution Earnings | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Ocular Therapeutix, Inc.this co. | OCUL | $1.9B | -7.25 | 2.94 | -40.6% | -5.07 |
| Progyny, Inc. | PGNY | $2.0B | 34.11 | 3.87 | 11.3% | 21.18 |
| Omnicell, Inc. | OMCL | $2.0B | 967.26 | 1.61 | 0.2% | 21.53 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | -46.25 | 10.79 | -23.3% | -45.92 |
| Iovance Biotherapeutics, Inc. | IOVA | $2.0B |
| - |
| - |
| - |
| - |
| - |
| - |
| -5.00 |
| 2.80 |
| -56.0% |
| -5.25 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.9B | 12.02 | 2.19 | 18.2% | 5.17 |
| Astrana Health, Inc. | ASTH | $1.9B | 83.46 | 2.41 | 2.9% | 18.67 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Peer Median | - | 3.51 | 3.33 | -0.9% | -0.04 | |